Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

37.41
-2.1600-5.46%
Volume:400.84K
Turnover:15.29M
Market Cap:4.06B
PE:-20.22
High:38.93
Open:38.14
Low:37.24
Close:39.57
52wk High:48.51
52wk Low:14.25
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.57
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:9.07
PE(LYR):-22.95

Loading ...

Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright

TIPRANKS
·
Jun 02

Edgewise Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Jun 02

Deals of the day-Mergers and acquisitions

Reuters
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

Wedbush Raises Price Target on Edgewise Therapeutics to $52 From $46, Maintains Outperform Rating

MT Newswires Live
·
Jun 02

Edgewise Therapeutics price target raised to $66 from $52 at Raymond James

TIPRANKS
·
Jun 02

Sector Update: Healthcare Stocks Fall in Afternoon Trading

MT Newswires Live
·
Jun 02

Edgewise Therapeutics deal ‘looks really strong,’ says Stifel

TIPRANKS
·
Jun 02

Edgewise Therapeutics rises 17.5%

TIPRANKS
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Apple, JetBlue, Cognizant

Reuters
·
Jun 01

Edgewise Therapeutics confirms sale of sevasemten for up to $2.65B

TIPRANKS
·
Jun 01

Edgewise Therapeutics Sells Sevasemten, Refocuses on Cardiology

TIPRANKS
·
Jun 01

Edgewise to Sell Muscular Dystrophy Unit in $2.65B Deal

Dow Jones
·
Jun 01

Edgewise Therapeutics Shares up 28% Premarket After Co to Sell Muscle Dystrophy Business to Servier for up to $2.65 Bln

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: Employees in Muscular Dystrophy Business to Receive Comparable Offers From Servier

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: Announces Sale of Sevasemten to Servier for up to $2.65 Bln

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: to Receive $1.55 Bln in Upfront Cash Consideration & Eligible for up to $1.1 Bln in Milestone Payments

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: Remains on Track to Initiate Phase 2 Trial of Edg-15400 in Heart Failure With Preserved Ejection Fraction

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: on Track to Report 12-Week Cirrus-HCM Part D Data in Q2 2026

THOMSON REUTERS
·
Jun 01

Servier to buy Edgewise muscular dystrophy business for up to $2.65 billion

Reuters
·
Jun 01